Martin Shkreli Loses $26 Million After Being Arrested
The price of his new company’s stock plummeted today on the news that Martin Shkreli was arrested Thursday morning.
Less than a month ago, Martin Shkreli invested in another pharmaceuticals company with the intent of repeating his drug price gouging act that earned him international condemnation. Shkreli bought his way into KaloBios, becoming its majority shareholder, CEO, and chairman. Shkreli invested millions into the company, and saw its stock soar to at one point 5000 percent higher. The stock when Shkreli bought the company last month was trading at $.90 a share, but “skyrocketed….to over $30.00 by the beginning of December.”
Upon news of Shkreli’s arrest on securities fraud this morning by the FBI, shares of KaloBios plummeted before trading was halted.
UPDATE:Â Martin Shkreli Ran Companies ‘Like A Ponzi Scheme’ Prosecutor Charges (Video)
“With the stock last changing hands at $11.03 in premarket trade prior to the halt, down $12.87, or 53%, from Wednesday’s closing price of $23.59, Shkreli’s stake was worth $26.7 million less than yesterday,” MarketWatch reports this morning.
Shkrlei’s net worth had been estimated at $100 million, but he is also being sued for $65 million by a former company, according to Heavy.
Â
Image via Martin Shkreli/Twitter
Enjoy this piece?
… then let us make a small request. The New Civil Rights Movement depends on readers like you to meet our ongoing expenses and continue producing quality progressive journalism. Three Silicon Valley giants consume 70 percent of all online advertising dollars, so we need your help to continue doing what we do.
NCRM is independent. You won’t find mainstream media bias here. From unflinching coverage of religious extremism, to spotlighting efforts to roll back our rights, NCRM continues to speak truth to power. America needs independent voices like NCRM to be sure no one is forgotten.
Every reader contribution, whatever the amount, makes a tremendous difference. Help ensure NCRM remains independent long into the future. Support progressive journalism with a one-time contribution to NCRM, or click here to become a subscriber. Thank you. Click here to donate by check.